ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 59.1 Cr.
- Current Price ₹ 45.3
- High / Low ₹ 86.1 / 43.0
- Stock P/E
- Book Value ₹ 56.2
- Dividend Yield 0.00 %
- ROCE 1.78 %
- ROE -8.72 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.81 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 1.60% over past five years.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 193 days.
- Working capital days have increased from 130 days to 213 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 34 | 37 | 55 | 67 | 75 | 121 | 126 | 154 | 349 | 207 | 131 | 100 | |
14 | 30 | 34 | 50 | 60 | 68 | 110 | 114 | 139 | 283 | 195 | 122 | 97 | |
Operating Profit | 3 | 5 | 3 | 5 | 6 | 7 | 12 | 12 | 15 | 66 | 12 | 10 | 3 |
OPM % | 16% | 14% | 8% | 9% | 10% | 10% | 10% | 10% | 10% | 19% | 6% | 7% | 3% |
0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 10 | -1 | 0 | |
Interest | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 8 | 11 | 10 | 9 |
Depreciation | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 9 | 8 | 7 |
Profit before tax | 0 | 0 | 1 | 2 | 4 | 5 | 8 | 8 | 10 | 53 | 2 | -9 | -13 |
Tax % | 140% | 56% | 32% | 25% | 26% | 25% | 30% | 28% | 26% | 25% | 132% | -2% | |
-0 | 0 | 0 | 2 | 3 | 4 | 6 | 6 | 7 | 40 | -1 | -9 | -12 | |
EPS in Rs | -0.07 | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -9.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 2% |
3 Years: | -5% |
TTM: | -37% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | -51% |
1 Year: | -37% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 15% |
3 Years: | 14% |
Last Year: | -9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 10 | 13 | 13 | 13 |
Reserves | -1 | -1 | -1 | 1 | 4 | 18 | 24 | 29 | 36 | 73 | 72 | 64 | 60 |
13 | 11 | 10 | 12 | 14 | 17 | 22 | 21 | 42 | 61 | 56 | 59 | 72 | |
6 | 11 | 13 | 19 | 25 | 28 | 30 | 39 | 58 | 124 | 111 | 81 | 72 | |
Total Liabilities | 21 | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 217 | 218 |
11 | 9 | 9 | 9 | 9 | 9 | 21 | 21 | 22 | 82 | 79 | 53 | 54 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
10 | 16 | 17 | 26 | 38 | 47 | 60 | 73 | 120 | 183 | 170 | 161 | 160 | |
Total Assets | 21 | 25 | 26 | 35 | 47 | 68 | 81 | 94 | 142 | 269 | 252 | 217 | 218 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-8 | 4 | 3 | 2 | 3 | 1 | 7 | 5 | -11 | 27 | 26 | -13 | |
-2 | -2 | -2 | -3 | -3 | -13 | -1 | -2 | -8 | -42 | -9 | 20 | |
10 | -1 | -1 | 2 | -0 | 13 | -4 | -4 | 19 | 15 | -17 | -7 | |
Net Cash Flow | 0 | 0 | -0 | 1 | -0 | 1 | 3 | -1 | -0 | 0 | -0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 96 | 80 | 62 | 109 | 139 | 156 | 126 | 133 | 139 | 104 | 138 | 193 |
Inventory Days | 137 | 84 | 84 | 47 | 45 | 53 | 27 | 41 | 68 | 46 | 93 | 143 |
Days Payable | 169 | 129 | 130 | 133 | 163 | 154 | 91 | 106 | 159 | 105 | 154 | 244 |
Cash Conversion Cycle | 63 | 34 | 16 | 22 | 21 | 56 | 62 | 69 | 48 | 45 | 77 | 92 |
Working Capital Days | 59 | 42 | 39 | 43 | 50 | 79 | 77 | 90 | 133 | 73 | 104 | 213 |
ROCE % | 20% | 14% | 17% | 26% | 29% | 22% | 24% | 22% | 20% | 54% | 9% | 2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
16 Dec - Resignation of Ms. Renu Kaur as Company Secretary.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Reg 30 & 47 of SEBI (LODR), 2015, Submission of Newspaper advertisement of Unaudited Financial Results for the Quarter and half year ended 30.09.2024.
- Financial Results For Quarter And Half Year Ended 30.09.2024. 14 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.11.2024
14 Nov - Unaudited financial results for Q2 and H1 2024.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015
7 Nov - Board meeting scheduled for financial results approval.
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)